On Friday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened lower -6.18% from the last session, before settling in for the closing price of $11.81. Price fluctuations for PHAT have ranged from $6.07 to $17.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -27.57% at the time writing. With a float of $27.99 million, this company’s outstanding shares have now reached $57.97 million.
The extent of productivity of a business whose workforce counts for 452 workers is very important to gauge.
Phathom Pharmaceuticals Inc (PHAT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 52.18%, while institutional ownership is 48.11%. The most recent insider transaction that took place on Apr 08 ’24, was worth 38,128. In this transaction CFO and CBO of this company sold 3,435 shares at a rate of $11.10, taking the stock ownership to the 95,263 shares. Before that another transaction happened on Mar 22 ’24, when Company’s President and Chief Executive sold 16,851 for $9.11, making the entire transaction worth $153,513. This insider now owns 410,784 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Latest Financial update
If we go through the results of last quarter, which was made public on 3/31/2024, the company posted -0.84 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.98) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.57% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 7.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 250.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.41, a number that is poised to hit -1.32 in the next quarter and is forecasted to reach -3.77 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
The latest stats from [Phathom Pharmaceuticals Inc, PHAT] show that its last 5-days average volume of 0.7 million was inferior to 0.74 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.76%. Additionally, its Average True Range was 0.82.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 75.02%, which indicates a significant increase from 48.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.72% in the past 14 days, which was lower than the 87.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.19, while its 200-day Moving Average is $9.35. Now, the first resistance to watch is $11.74. This is followed by the second major resistance level at $12.41. The third major resistance level sits at $12.87. If the price goes on to break the first support level at $10.61, it is likely to go to the next support level at $10.15. The third support level lies at $9.48 if the price breaches the second support level.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 58,535K shares outstanding in the company with a market cap of 648.62 million. Presently, the company’s annual sales total 680 K according to its annual income of -201,590 K. Last quarter, the company’s sales amounted to 1,910 K and its income totaled -82,850 K.
